about
Therapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewManaging synchronous liver metastases from colorectal cancer: a multidisciplinary international consensusFOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyEnd points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancerAssociation between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesIntrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.Pemetrexed in patients with gastrointestinal carcinoma.Colorectal cancer: integrating oxaliplatin.Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studySTRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.The ARCAD clinical trials program: an update and invitation.Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III TrialFirst-line therapy for advanced colorectal cancer.Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.Adjuvant therapy of stage II and III colon cancer.Current issues in adjuvant treatment of stage II colon cancer.Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer.Targeted agents for adjuvant therapy of colon cancer.Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT databaseAdjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.Accomplishments in 2007 in the adjuvant treatment of colorectal cancerAccomplishments in 2008 in the adjuvant treatment of colon cancer.Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.A catalyst for change: the European cancer Patient's Bill of Rights.Biomarkers and surrogate end points--the challenge of statistical validation.Stage II and stage III colon cancer: treatment advances and future directions.Integrating biomarkers in clinical trials.
P50
Q26775522-904A6FDD-670F-44C0-B076-50D06A140440Q26784531-3ECBCAD4-78C0-4F33-9CA8-178C92111B03Q28189472-559A4EB9-1702-4077-A1DF-57EFA784F0AEQ31129788-DD32BA77-FB9F-4D13-8A04-E6A2B6A7EF6DQ33364579-DA16E3E9-2E2C-4500-AEF0-85048AF38014Q33372496-724E6C51-1001-4494-8D9C-20F641BD5BC2Q33397671-4DDA272A-D44F-4B45-AE28-64E975168CCEQ33414068-17511ACA-D39B-4825-AE8D-636FC971D769Q33518321-AE1D19E0-0710-4628-B94B-ADA2F5C41109Q33634975-766E210F-B5CB-4015-B366-27219C222F0BQ33645784-B1F3C1E9-F03C-4860-9355-3EE8C30F6168Q33696582-D228605B-9CDD-4B97-9372-393B43A79B76Q34023788-6D60DFB1-D47A-4419-B8F4-CF84A584CDD2Q34103998-FB53B057-A6A9-41CA-8227-6236F350FF34Q34581388-29E94CCB-C04E-423F-9B89-A9BDDF94F4B3Q34607843-9C177C92-A454-43AA-894B-2D6917B112D6Q34649653-72091AE1-6121-4B20-880B-BC4AB5485800Q35206803-523AA9CF-DCB0-4AC5-BCAB-D55726A4160AQ35549302-4A3563E3-7E5F-40C6-979F-B3F8D24D3E14Q35584825-B35F09EC-3C18-4363-B39C-92F538196853Q35682543-E909ED6A-B6F1-4594-A81D-B11586BA59F6Q35776224-FA68E043-0952-4C50-ADB1-DD1AF4423CD1Q36054226-B8F39E89-E1D7-41EC-A20D-B02A7564DAE2Q36104929-4541C269-AEF7-4299-AC73-D53175F27A03Q36319045-F148D6C6-0AAE-427B-B562-03ABC1C33BA9Q36344594-66C1588E-864C-406C-851E-C0A91A4514FCQ36449275-A05FD157-B0D7-4610-939E-6FBB8B616E90Q36539266-9EE3975C-CB72-4D13-8D36-567453D15C30Q36687650-2B2A6EA3-5A5D-4C88-BB47-99A982D82E47Q36733282-8F2894F9-4A67-4F60-8803-BA73F24DE407Q36920315-F5C2998D-A944-4491-B24C-BDB20D3CD34CQ36977050-66365A4B-4E71-41E3-993D-705AB2848C98Q37076532-BFFE77F5-80F7-4945-A656-2DDD2E59600BQ37149152-243EF87D-ECB4-4494-BAFF-7BAF9CF64B43Q37468817-95196C78-3B01-440F-A181-33D68E074028Q37592789-7B4981DA-F58F-4B4E-A8F5-A058E65062E1Q37644553-09A25ADB-CF7C-4EA8-BD11-A16549565BD0Q37724573-9B830ABA-0553-4F17-BE49-D4F6D3DDECF9Q37762938-BEF2EAAF-B12B-479F-897A-247352E03891Q37853183-9A4D3C1B-5C27-4714-981D-AF6EBE6DC565
P50
description
onderzoeker
@nl
name
Aimery de Gramont
@ast
Aimery de Gramont
@en
Aimery de Gramont
@es
type
label
Aimery de Gramont
@ast
Aimery de Gramont
@en
Aimery de Gramont
@es
prefLabel
Aimery de Gramont
@ast
Aimery de Gramont
@en
Aimery de Gramont
@es
P106
P21
P31
P569
2000-01-01T00:00:00Z